PubMed

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.PMID: 14734330 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.

Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM.

Kidney Int. 2003 Mar;63(3):1051-7.PMID: 12631087 [PubMed - indexed for MEDLINE]Related articles

An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.

Bone Marrow Transplant. 2001 Oct;28(7):637-42. Review.PMID: 11704785 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL, Falk RH, Skinner M.

Ann Intern Med. 2001 May 1;134(9 Pt 1):746-53.PMID: 11329232 [PubMed - indexed for MEDLINE]Related articlesFree article

Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.

Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.

Am J Kidney Dis. 2005 Aug;46(2):270-7. Review.PMID: 16112045 [PubMed - indexed for MEDLINE]Related articles

Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M.

Blood. 1996 Oct 1;88(7):2801-6.PMID: 8839879 [PubMed - indexed for MEDLINE]Related articlesFree article

Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M.

Blood. 1998 May 15;91(10):3662-70.PMID: 9573002 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.

Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.

Br J Haematol. 2004 Dec;127(5):543-51.PMID: 15566357 [PubMed - indexed for MEDLINE]Related articles

Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.

Girnius S, Seldin DC, Skinner M, Finn KT, Quillen K, Doros G, Sanchorawala V.

Haematologica. 2009 Jul;94(7):1029-32. Epub 2009 May 19.PMID: 19454500 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.

Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M.

Bone Marrow Transplant. 2004 Feb;33(4):381-8.PMID: 14676787 [PubMed - indexed for MEDLINE]Related articles

Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.

Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.

Wien Klin Wochenschr. 2006 Feb;118(1-2):49-53.PMID: 16489526 [PubMed - indexed for MEDLINE]Related articles

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.

N Engl J Med. 2007 Sep 13;357(11):1083-93.PMID: 17855669 [PubMed - indexed for MEDLINE]Related articlesFree article

Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.

Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V.

Blood. 2006 Dec 1;108(12):3945-7. Epub 2006 Aug 22.PMID: 16926284 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.

Haematologica. 2006 Dec;91(12):1635-43.PMID: 17145600 [PubMed - indexed for MEDLINE]Related articlesFree article

Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.

Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F.

Arch Cardiovasc Dis. 2008 Sep;101(9):523-32. Epub 2008 Nov 17.PMID: 19041836 [PubMed - indexed for MEDLINE]Related articles

[High-dose melphalan treatment followed by hematopoietic progenitor cell rescue in primary amyloidosis]

Rives S, Bladé J, Martínez C, Marín P, Carreras E, Montserrat E.

Med Clin (Barc). 2000 Jul 8;115(6):216-20. Spanish. Erratum in: Med Clin (Barc) 2000 Oct 21;115(13):486. PMID: 11002461 [PubMed - indexed for MEDLINE]Related articles

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.

Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR.

Bone Marrow Transplant. 2004 Dec;34(12):1025-31.PMID: 15516945 [PubMed - indexed for MEDLINE]Related articles

High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.

Vesole DH, Pérez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Mayo Clin Proc. 2006 Jul;81(7):880-8.PMID: 16835967 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.

Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D, Gillmore J, Mathias CJ, Hawkins PN, Apperley JF.

Bone Marrow Transplant. 2006 May;37(10):937-43.PMID: 16565738 [PubMed - indexed for MEDLINE]Related articles

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG.

Bone Marrow Transplant. 2005 Oct;36(7):597-600.PMID: 16044137 [PubMed - indexed for MEDLINE]Related articles